The global plasmid DNA contract manufacturing market accounted for USD 0.329 billion in 2023 and is expected to reach USD 2.29 billion by 2034 with a CAGR of 19.33% during the forecast period 2024-2034. The market will grow as a result of factors such as growing demand for nucleic acid vaccines and gene therapies, biotechnology advancements, an increased emphasis on research and development, outsourcing manufacturing needs, and an increase in partnerships and collaborations.
The creation of nucleic acid vaccines and gene treatments depends heavily on plasmid DNA. Nucleic acid vaccines have become an effective weapon in the fight against infectious diseases, while gene therapy provides potential new treatments for a variety of ailments. The market for plasmid DNA contract manufacturing is driven by the rising demand for these medicines due to the rising prevalence of chronic illnesses and the growing emphasis on personalized medicine. For instance, in October 2023, VGXI, Inc. and WuXi AppTec announced a partnership to provide integrated AAV (adeno-associated virus) vector and plasmid DNA production services, aiming to serve the expanding gene therapy market.
By application, the cell and gene therapy segment accounted for the highest revenue-grossing segment in the global plasmid DNA contract manufacturing market in 2023 owing to the rapid expansion of cell and gene therapy research and development, increasing demand for personalized medicines, and advancements in biotechnology enabling more efficient production processes. For instance, Waisman Biomanufacturing announced in December 2022 that it was expanding its plasmid DNA manufacturing plant to accommodate the growing demand for gene therapy applications. Additionally, the immunotherapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of cancer and autoimmune diseases, along with the rising adoption of immunotherapy as a promising treatment modality due to its ability to harness the body's immune system to target and eradicate the disease.
By therapeutic area, the cancer segment accounted for the highest revenue-grossing segment in the global plasmid DNA contract manufacturing market in 2023 owing to the growing incidence of cancer worldwide, coupled with the development of gene-based cancer therapies and personalized treatment approaches utilizing plasmid DNA technology. For instance, Charles River Laboratories launched the eXpDNATM plasmid manufacturing platform in January 2023 to enable GMP-grade plasmid synthesis more quickly and effectively. Additionally, the infectious diseases segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing global concern over infectious disease outbreaks, the demand for rapid vaccine development, and the utilization of plasmid DNA technology in the production of vaccines for various infectious diseases.
By end-user, the pharmaceutical and biotechnology companies segment accounted for the highest revenue-grossing segment in the global plasmid DNA contract manufacturing market in 2023 owing to the increased outsourcing of plasmid DNA manufacturing activities by pharmaceutical and biotechnology companies to specialized contract manufacturers, enabling them to focus on core competencies and accelerate the development and commercialization of gene-based therapies and vaccines. For instance, in January 2023, Syngene International Limited announced the development of its viral vector production plant in Bengaluru, India, to meet the rising demand for gene therapy products. Additionally, the research institutes segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding research initiatives in gene therapy, vaccine development, and genetic engineering, driving the demand for plasmid DNA contract manufacturing services among research institutes aiming to translate scientific discoveries into clinical applications.
North American region is anticipated to have the highest revenue share during the forecast period owing to the establishment of a robust biopharmaceutical industry, strong government support for biotechnology research and development, and a favorable regulatory environment facilitating the commercialization of gene-based therapies and vaccines. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing investments in healthcare infrastructure, rising adoption of advanced biotechnologies, expanding pharmaceutical manufacturing capabilities, and a growing focus on addressing unmet medical needs, particularly in emerging economies within the region. For instance, in October 2023, LakePharma, Inc. announced the acquisition of Blue Sky BioServices, which will increase its contract manufacturing capabilities for cell and gene therapies.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
The creation of nucleic acid vaccines and gene treatments depends heavily on plasmid DNA. Nucleic acid vaccines have become an effective weapon in the fight against infectious diseases, while gene therapy provides potential new treatments for a variety of ailments. The market for plasmid DNA contract manufacturing is driven by the rising demand for these medicines due to the rising prevalence of chronic illnesses and the growing emphasis on personalized medicine. For instance, in October 2023, VGXI, Inc. and WuXi AppTec announced a partnership to provide integrated AAV (adeno-associated virus) vector and plasmid DNA production services, aiming to serve the expanding gene therapy market.
By application, the cell and gene therapy segment accounted for the highest revenue-grossing segment in the global plasmid DNA contract manufacturing market in 2023 owing to the rapid expansion of cell and gene therapy research and development, increasing demand for personalized medicines, and advancements in biotechnology enabling more efficient production processes. For instance, Waisman Biomanufacturing announced in December 2022 that it was expanding its plasmid DNA manufacturing plant to accommodate the growing demand for gene therapy applications. Additionally, the immunotherapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of cancer and autoimmune diseases, along with the rising adoption of immunotherapy as a promising treatment modality due to its ability to harness the body's immune system to target and eradicate the disease.
By therapeutic area, the cancer segment accounted for the highest revenue-grossing segment in the global plasmid DNA contract manufacturing market in 2023 owing to the growing incidence of cancer worldwide, coupled with the development of gene-based cancer therapies and personalized treatment approaches utilizing plasmid DNA technology. For instance, Charles River Laboratories launched the eXpDNATM plasmid manufacturing platform in January 2023 to enable GMP-grade plasmid synthesis more quickly and effectively. Additionally, the infectious diseases segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing global concern over infectious disease outbreaks, the demand for rapid vaccine development, and the utilization of plasmid DNA technology in the production of vaccines for various infectious diseases.
By end-user, the pharmaceutical and biotechnology companies segment accounted for the highest revenue-grossing segment in the global plasmid DNA contract manufacturing market in 2023 owing to the increased outsourcing of plasmid DNA manufacturing activities by pharmaceutical and biotechnology companies to specialized contract manufacturers, enabling them to focus on core competencies and accelerate the development and commercialization of gene-based therapies and vaccines. For instance, in January 2023, Syngene International Limited announced the development of its viral vector production plant in Bengaluru, India, to meet the rising demand for gene therapy products. Additionally, the research institutes segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding research initiatives in gene therapy, vaccine development, and genetic engineering, driving the demand for plasmid DNA contract manufacturing services among research institutes aiming to translate scientific discoveries into clinical applications.
North American region is anticipated to have the highest revenue share during the forecast period owing to the establishment of a robust biopharmaceutical industry, strong government support for biotechnology research and development, and a favorable regulatory environment facilitating the commercialization of gene-based therapies and vaccines. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing investments in healthcare infrastructure, rising adoption of advanced biotechnologies, expanding pharmaceutical manufacturing capabilities, and a growing focus on addressing unmet medical needs, particularly in emerging economies within the region. For instance, in October 2023, LakePharma, Inc. announced the acquisition of Blue Sky BioServices, which will increase its contract manufacturing capabilities for cell and gene therapies.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Application, Therapeutic Area, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Plasmid DNA Contract Manufacturing Market Report 2023 - 2034
Plasmid DNA Contract Manufacturing Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Cell and Gene Therapy
- Immunotherapy
- Others
Plasmid DNA Contract Manufacturing Market Analysis & Forecast by Therapeutic Area 2023 - 2034 (Revenue USD Bn)
- Cancer
- Infectious Diseases
- Autoimmune Diseases
- Cardiovascular Diseases
- Others
Plasmid DNA Contract Manufacturing Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Pharmaceutical and Biotechnology Companies
- Research Institutes
- Others
Plasmid DNA Contract Manufacturing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Plasmid DNA Contract Manufacturing Market: Application Estimates & Trend Analysis
8. Plasmid DNA Contract Manufacturing Market: Therapeutic Area Estimates & Trend Analysis
9. Plasmid DNA Contract Manufacturing Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Plasmid DNA Contract Manufacturing Market
12. Europe Global Plasmid DNA Contract Manufacturing Market
13. Asia Pacific Global Plasmid DNA Contract Manufacturing Market
14. Latin America Global Plasmid DNA Contract Manufacturing Market
15. MEA Global Plasmid DNA Contract Manufacturing Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Aldevron
- Cobra Biologics
- Fujifilm Diosynth Biotechnologies
- VGXI Inc.
- Waisman Biomanufacturing
- LakePharma Inc.
- Richter-Helm BioLogics
- PlasmidFactory GmbH & Co. KG
- Nature Technology Corporation
- Syngene International Limited
- Cell and Gene Therapy Catapult
- Eurofins Genomics
- Vigene Biosciences
- Kaneka Eurogentec
- Genscript Biotech Corporation.
